PT  - JOURNAL ARTICLE
AU  - González-González, Everardo
AU  - Santiago, Grissel Trujillo-de
AU  - Lara-Mayorga, Itzel Montserrat
AU  - Martínez-Chapa, Sergio Omar
AU  - Alvarez, Mario Moisés
TI  - Portable and accurate diagnostics for COVID-19: Combined use of the miniPCR® thermocycler and a well-plate reader for SARS-Co2 virus detection
AID  - 10.1101/2020.04.03.20052860
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.04.03.20052860
4099  - http://medrxiv.org/content/early/2020/04/07/2020.04.03.20052860.short
4100  - http://medrxiv.org/content/early/2020/04/07/2020.04.03.20052860.full
AB  - The COVID-19 pandemic has crudely demonstrated the value of massive and rapid diagnostics. By the first week of April, more than 900,000 positive cases of COVID-19 have been reported worldwide, although this number could be greatly underestimated. In the case of an epidemic emergency, the first line of response should be based on commercially available and validated resources. Here, we demonstrate the combined use of the miniPCR®, a commercial compact and portable PCR device recently available on the market, and a commercial well-plate reader as a diagnostic system for detecting SARS-CoV2 nucleic acids. We used the miniPCR to detect and amplify SARS-CoV2 DNA sequences using the sets of initiators recommended by the World Health Organization for targeting three different regions that encode for the N protein. Prior to amplification, samples were combined with a DNA intercalating reagent (i.e., EvaGreen® Dye). Sample fluorescence after amplification was then read using a commercial 96-well plate reader. This straightforward method allows the detection and amplification of SARS-CoV2 nucleic acids in the range of ∼625 to 2×105 DNA copies. The accuracy and simplicity of this diagnostics strategy may provide a cost-efficient and reliable alternative for COVID-19 pandemic testing, particularly in underdeveloped regions where RT-QPCR instrument availability may be limited. In addition, the portability, ease of use, and reproducibility of the miniPCR® makes it a reliable alternative for deployment in point-of-care SARS-CoV2 detection efforts during pandemics.Competing Interest StatementThe authors have declared no competing interest.Funding StatementWe acknowledge funding provided by Consejo Nacional de Ciencia y Tecnología (CONACyT), México.Author DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe set of raw data used to produce the graphs reported here is all presented within this manuscript or provided as supplementary material